Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ventana Launches First Fully Automated IHC Test

Published: Thursday, October 03, 2013
Last Updated: Thursday, October 03, 2013
Bookmark and Share
Exclusive license agreement paves the way for industry's first BRAF V600E IHC test.

Ventana Medical Systems, Inc. has announced the global launch of the industry's first BRAF V600E immunohistochemistry (IHC) test to detect the BRAF V600E mutation in a variety of tumors.

The test is designed to detect the most frequent BRAF mutation, V600E, which has been found to play a key role in a variety of cancers including colorectal cancer-the third most common type of cancer and third leading cause of cancer deaths worldwide.

The BRAF V600E mutation is also known to play a role in other cancers such as melanoma, papillary thyroid cancer and hairy cell leukemia.

"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President Mara G. Aspinall.

Aspinall continued, "The BRAF V600E (VE1) IHC in vitro diagnostic is a valuable addition to our assay portfolio to aid physicians and patients in the important stratification of colon cancer."

The Ventana BRAF V600E (VE1) Mouse Monoclonal Primary Antibody IHC assay is the result of the company's exclusive license agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the University Hospital Heidelberg, Germany to commercialize the novel IHC primary antibody that detects the V600E mutated BRAF protein.

It is the only fully automated IHC test providing lab professionals and pathologists with a highly sensitive and specific, standardized testing method for the assessment of the BRAF V600E mutation in tissue.

The assay is optimized to perform on all VENTANA Benchmark IHC platforms with the OptiView DAB IHC Detection Kit, providing easy interpretation and seamless integration into a laboratory's workflow.

Roche also offers the cobas® 4800 BRAF V600 Mutation Test which is the companion diagnostic for Zelboraf ® (vemurafenib). This test was clinically validated to select patients in the pivotal BRIM-3 study, and only patients selected by this test were shown to benefit from Zelboraf therapy.

The new Ventana IHC BRAF assay expands Roche's offering in BRAF V600E testing into disease areas beyond melanoma.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ventana, MedImmune to Develop a custom Assay Immunotherapy for Clinical Trials
Companies are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma.
Thursday, June 05, 2014
Ventana and Bayer Extend Collaboration
The multi-year agreement to develop companion diagnostics focuses on immunohistochemistry.
Thursday, March 13, 2014
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!